Back to today’s briefing

Story perspectives

Sarepta's Gene Therapy Crisis: Stock Plummets 90% Amid Safety Warnings

7/26/2025

40 6

Summary

Story summary

Sarepta Therapeutics is in turmoil as its gene therapy, Elevidys, faces severe scrutiny after the FDA issued safety warnings tied to patient deaths. The European Medicines Agency's rejection further complicates matters, causing Sarepta's stock to nosedive over 90%. In response, the company is pivoting to RNA-based therapies, urging investors to seek firms with strong safety measures and diverse offerings.

1 of 1

Story summary

Sarepta Therapeutics is in turmoil as its gene therapy, Elevidys, faces severe scrutiny after the FDA issued safety warnings tied to patient deaths. The European Medicines Agency's rejection further complicates matters, causing Sarepta's stock to nosedive over 90%. In response, the company is pivoting to RNA-based therapies, urging investors to seek firms with strong safety measures and diverse offerings.